Ado-tratuzumab emtansine beyond breast cancer: therapeutic role of targeting other HER2-positive cancers

Ado-trastuzumab emtansine (T-DM1) is an antibody–drug conjugate approved by the FDA in 2013 for advanced HER2-positive breast cancer treatment exhibiting promising clinical benefits. However, HER2 overexpression and gene amplification have also been reported in other cancers like gastric cancer, non...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Yang, Zou, Jiayu, Sun, Chen, Peng, Fu, Peng, Cheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Molecular Biosciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10210145/
https://www.ncbi.nlm.nih.gov/pubmed/37251081
http://dx.doi.org/10.3389/fmolb.2023.1165781

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10210145/
https://www.ncbi.nlm.nih.gov/pubmed/37251081
http://dx.doi.org/10.3389/fmolb.2023.1165781

Ejemplares similares